Anti-RSV glycoprotein F Recombinant Antibody (TAB-709)

Customer Review

There are currently no Customer reviews or questions for TAB-709. Click the button above to contact us or submit your feedback about this product.

Emily Roberts
12.Sep,23

Great for RSV Glycoprotein F

The Anti-RSV Glycoprotein F Therapeutic Antibody (NUMAX) has been excellent for our RSV glycoprotein F studies. Its specificity and sensitivity are top-notch, providing clear and reliable results. This antibody has significantly improved the accuracy of our experiments and saved us a lot of troubleshooting time.

Brian Anderson
21.Oct,22

Effective in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for RSV glycoprotein F is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Jessica Moore
17.May,21

Consistent and High-Quality

This antibody has proven to be consistent and high-quality in our assays. The reproducible results and strong affinity for RSV glycoprotein F have significantly improved our experiments, making it a crucial part of our research toolkit. The consistent performance has greatly enhanced our data quality.

Q&As

1. Is the anti-RSV glycoprotein F therapeutic antibody NUMAX suitable for use in Western blotting?

   A: Yes, the anti-RSV glycoprotein F therapeutic antibody NUMAX (TAB-709) is suitable for use in Western blotting. It provides specific binding to glycoprotein F, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-RSV glycoprotein F therapeutic antibody NUMAX?

   A: The recommended storage condition for the anti-RSV glycoprotein F therapeutic antibody NUMAX (TAB-709) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-RSV glycoprotein F therapeutic antibody NUMAX be used in immunoprecipitation assays?

   A: Yes, the anti-RSV glycoprotein F therapeutic antibody NUMAX (TAB-709) can be used in immunoprecipitation assays. It provides specific binding to glycoprotein F, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-RSV glycoprotein F therapeutic antibody NUMAX effective in ELISA applications?

   A: Yes, the anti-RSV glycoprotein F therapeutic antibody NUMAX (TAB-709) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of glycoprotein F.

5. What is the optimal dilution for using the anti-RSV glycoprotein F therapeutic antibody NUMAX in immunofluorescence?

   A: The optimal dilution for using the anti-RSV glycoprotein F therapeutic antibody NUMAX (TAB-709) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Tang, Wei, et al. "Mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in respiratory syncytial virus fusion protein." Journal of Virology 95.20 (2021): 10-1128.
   This study investigates the mechanism of cross-resistance to fusion inhibitors conferred by the K394R mutation in the respiratory syncytial virus (RSV) fusion protein. The researchers employed a dual-luciferase protocol to discover LF-6, a small-molecule inhibitor that targets the RSV fusion glycoprotein. They found that the K394R mutation not only conferred resistance to LF-6 but also to other RSV fusion inhibitors, including those in clinical development. This mutation destabilizes the F protein and enhances its membrane fusion activity, increasing viral resistance. The study highlights the need for alternative strategies to combat RSV infections, given the resistance risks posed by the K394R mutation.
   In this research, Creative Biolabs provided crucial reagents that facilitated the experiments. Specifically, the D25 monoclonal antibody (Cat# PABL-322) and Motavizumab (Cat# TAB-709) were used for detecting RSV F protein in various assays, including the immunofluorescence and cell-surface triggering assays. These antibodies were essential for accurately identifying the effects of mutations on the RSV F protein and assessing the resistance mechanisms. The products from Creative Biolabs significantly contributed to the detailed analysis and validation of the findings related to the K394R mutation and its impact on RSV fusion inhibitor resistance​.
2. Henry, Kevin A., et al. "Isolation of TGF-β-neutralizing single-domain antibodies of predetermined epitope specificity using next-generation DNA sequencing." Protein Engineering, Design and Selection 29.10 (2016): 439-443. https://doi.org/10.1093/protein/gzw043
   The research presents a novel strategy for isolating single-domain antibodies (sdAbs) with predetermined epitope specificity against TGF-β3, specifically targeting the interaction site between the cytokine and its type II cell-surface receptor. By combining phage display technology with next-generation DNA sequencing (NGS) and competitive elution using soluble dimeric type II receptor ectodomain, the researchers successfully identified several sdAbs that effectively compete with the receptor for TGF-β3 binding. These antibodies demonstrated the ability to neutralize TGF-β3 in cellular assays, whereas conventional panning approaches failed to yield antibodies targeting this specific epitope. The identified sdAbs showed binding affinities to TGF-β3 ranging from 12 to 284 nM, with some cross-reactivity to TGF-β2 but minimal binding to TGF-β1.
   Creative Biolabs provided Synagis® (anti-RSV glycoprotein F antibody) which served as an irrelevant competitor in the competitive elution experiments during the phage display selection process. This contribution was crucial for the comparative analysis that enabled the researchers to distinguish epitope-specific sdAbs from non-specific binders. The availability of this control antibody strengthened the methodology's validity and helped establish this approach as a generalizable strategy for identifying epitope-specific antibodies when binding reagents against the epitope of interest are available, potentially advancing the development of cancer immunotherapeutics targeting the TGF-β pathway.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-709, RRID: AB_3111987)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Motavizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Motavizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "RSV F"

Select a product category from the dropdown menu below to view related products.